Published in J Clin Endocrinol Metab on June 10, 2014
Letter to the editor: denosumab for “resistant” hypercalcemia in patients with impaired renal function. J Clin Endocrinol Metab (2015) 1.09
Hypercalcemia of Malignancy: An Update on Pathogenesis and Management. N Am J Med Sci (2015) 0.90
Hypercalcemia of malignancy and new treatment options. Ther Clin Risk Manag (2015) 0.85
Denosumab: a new agent in the management of hypercalcemia of malignancy. Future Oncol (2015) 0.79
AACR Cancer Progress Report 2015. Clin Cancer Res (2015) 0.75
Response letter to the editor. J Clin Endocrinol Metab (2015) 0.75
Hypercalcemia of Malignancy. J Adv Pract Oncol (2015) 0.75
Hypercalcemia of Malignancy in Thymic Carcinoma: Evolving Mechanisms of Hypercalcemia and Targeted Therapies. Case Rep Endocrinol (2017) 0.75
Hypercalcemia of Malignancy and Colorectal Cancer. World J Oncol (2016) 0.75
Hypercalcaemia and hypocalcaemia: finding the balance. Support Care Cancer (2017) 0.75
Prevalence of hypercalcemia of malignancy among pediatric cancer patients in the UK Clinical Practice Research Datalink database. Clin Epidemiol (2017) 0.75
Denosumab: an Emerging Therapy in Pediatric Bone Disorders. Curr Osteoporos Rep (2017) 0.75
Clinical Assessment and Management of Delirium in the Palliative Care Setting. Drugs (2017) 0.75
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet (2011) 11.28
Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol (2010) 9.29
Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol (2010) 6.47
Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol (2011) 6.16
Clinical practice. Hypercalcemia associated with cancer. N Engl J Med (2005) 3.88
Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol (2013) 3.23
Parathyroid hormone-related protein purified from a human lung cancer cell line. Proc Natl Acad Sci U S A (1987) 3.06
Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment. J Natl Cancer Inst (2013) 2.80
Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol (2001) 2.72
Cancer-associated hypercalcemia: morbidity and mortality. Clinical experience in 126 treated patients. Ann Intern Med (1990) 2.43
Parathyroid hormonelike protein from human renal carcinoma cells. Structural and functional homology with parathyroid hormone. J Clin Invest (1987) 2.41
Identification of a novel 17,000-dalton parathyroid hormone-like adenylate cyclase-stimulating protein from a tumor associated with humoral hypercalcemia of malignancy. J Biol Chem (1987) 2.30
Narrative review: furosemide for hypercalcemia: an unproven yet common practice. Ann Intern Med (2008) 2.23
The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy. Endocrinology (2005) 1.78
Hypercalcemia of malignancy: the central role of parathyroid hormone-related protein. Annu Rev Med (1994) 1.49
Therapeutic efficacy of a soluble receptor activator of nuclear factor kappaB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy. Cancer Res (2001) 1.13
Onco-nephrology: the pathophysiology and treatment of malignancy-associated hypercalcemia. Clin J Am Soc Nephrol (2012) 1.07
Zoledronic acid in the treatment of hypercalcemia of malignancy: results of the international clinical development program. Semin Oncol (2001) 0.92
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol (2010) 13.25
High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med (2002) 11.28
Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol (2010) 9.29
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med (2014) 4.81
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer (2012) 4.29
Strategies of radioiodine ablation in patients with low-risk thyroid cancer. N Engl J Med (2012) 3.86
PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol (2009) 3.48
New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol (2012) 3.35
Aprepitant for erlotinib-induced pruritus. N Engl J Med (2010) 2.97
Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med (2012) 2.82
Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment. J Natl Cancer Inst (2013) 2.80
Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial. Lancet Oncol (2008) 2.40
Optimization of staging of the neck with prophylactic central and lateral neck dissection for papillary thyroid carcinoma. Ann Surg (2012) 2.35
Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol (2008) 2.32
Prophylactic lymph node dissection for papillary thyroid cancer less than 2 cm: implications for radioiodine treatment. J Clin Endocrinol Metab (2008) 2.30
Histologic results of para-aortic lymphadenectomy in patients treated for stage IB2/II cervical cancer with negative [18F]fluorodeoxyglucose positron emission tomography scans in the para-aortic area. J Clin Oncol (2008) 2.23
Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. Eur J Endocrinol (2008) 2.23
The succinate dehydrogenase genetic testing in a large prospective series of patients with paragangliomas. J Clin Endocrinol Metab (2009) 2.22
High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice. Oncologist (2008) 2.22
Assessment of the cost of fine-needle aspiration cytology as a diagnostic tool in patients with thyroid nodules. Am J Clin Pathol (2008) 2.18
Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin Cancer Res (2007) 2.18
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol (2007) 2.08
Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncol (2011) 2.06
[Senile systemic amyloidosis: definition, diagnosis, why thinking about?]. Presse Med (2013) 2.00
Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer. J Clin Oncol (2008) 1.99
Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood (2005) 1.99
Management of retropharyngeal node metastases from thyroid carcinoma. World J Surg (2015) 1.98
Infections in 252 patients with common variable immunodeficiency. Clin Infect Dis (2008) 1.93
Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study. Lancet Oncol (2012) 1.75
Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses. J Clin Oncol (2006) 1.69
Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin Cancer Res (2002) 1.66
Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire. J Clin Oncol (2008) 1.65
Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res (2003) 1.61
Multisystem study of 20 older adults with Williams syndrome. Am J Med Genet A (2004) 1.61
Characterization and fate of telomerase-expressing epithelia during kidney repair. J Am Soc Nephrol (2011) 1.52
Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients. PLoS One (2011) 1.44
MUC2 but not MUC5 expression correlates with prognosis in radically resected pancreatic cancer patients. Cancer Biol Ther (2009) 1.42
CD68-positive tumor-associated macrophages predict unfavorable treatment outcomes in classical Hodgkin lymphoma in correlation with interim fluorodeoxyglucose-positron emission tomography assessment. Leuk Lymphoma (2014) 1.40
Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. Oncologist (2010) 1.35
Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study. Blood (2010) 1.34
Fever after zoledronic acid administration is due to increase in TNF-alpha and IL-6. J Interferon Cytokine Res (2003) 1.34
Ectopic adrenocorticotropic hormone-syndrome in medullary carcinoma of the thyroid: a retrospective analysis and review of the literature. Thyroid (2005) 1.32
Are G3 ENETS neuroendocrine neoplasms heterogeneous? Endocr Relat Cancer (2013) 1.31
The biological properties of cetuximab. Crit Rev Oncol Hematol (2008) 1.31
Prognostic parameters of metastatic adrenocortical carcinoma. J Clin Endocrinol Metab (2006) 1.30
Al amyloidosis. Orphanet J Rare Dis (2012) 1.29
Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer. Eur J Cancer (2008) 1.27
Expression pattern of receptor activator of NFκB (RANK) in a series of primary solid tumors and related bone metastases. J Cell Physiol (2011) 1.27
Assessment of interobserver reproducibility in quantitative 18F-FDG PET and CT measurements of tumor response to therapy. J Nucl Med (2009) 1.27
Cardiac amyloidosis: updates in diagnosis and management. Arch Cardiovasc Dis (2013) 1.26
Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid. Clin Cancer Res (2012) 1.26
Practical guidelines for the supplementation of vitamin D and the treatment of deficits in Central Europe - recommended vitamin D intakes in the general population and groups at risk of vitamin D deficiency. Endokrynol Pol (2013) 1.25
Emerging anti-cancer molecular mechanisms of aminobisphosphonates. Endocr Relat Cancer (2006) 1.25
Longterm results after resection of simultaneous and sequential lung and liver metastases from colorectal carcinoma. J Am Coll Surg (2003) 1.19
131I effective half-life and dosimetry in thyroid cancer patients. J Nucl Med (2008) 1.17
Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer. J Clin Endocrinol Metab (2003) 1.17
Transarterial chemoembolization of liver metastases from well differentiated gastroenteropancreatic endocrine tumors with doxorubicin-eluting beads: preliminary results. J Vasc Interv Radiol (2008) 1.17
A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients. Cancer Immunol Immunother (2005) 1.17
In vivo effects of zoledronic acid on peripheral gammadelta T lymphocytes in early breast cancer patients. Cancer Immunol Immunother (2008) 1.16
Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J Clin Endocrinol Metab (2007) 1.16
Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients. J Interferon Cytokine Res (2005) 1.16
Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy. Int J Radiat Oncol Biol Phys (2004) 1.15
Effects of pegfilgrastim on normal biodistribution of 18F-FDG: preclinical and clinical studies. J Nucl Med (2006) 1.14
Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy. J Clin Oncol (2006) 1.14
Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study. Br J Haematol (2006) 1.13
Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid. Support Care Cancer (2013) 1.12
Efficacy of lenalidomide in POEMS syndrome: a retrospective study of 20 patients. Am J Hematol (2013) 1.11
Methylenetetrahydrofolate reductase 677C/T gene polymorphism, gastric cancer susceptibility and genomic DNA hypomethylation in an at-risk Italian population. Int J Cancer (2006) 1.11
Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas. J Clin Endocrinol Metab (2012) 1.11
The effect of aging on the skeletal response to intermittent treatment with parathyroid hormone. Endocrinology (2004) 1.09
Staging of peritoneal carcinomatosis: enhanced CT vs. PET/CT. Abdom Imaging (2007) 1.08
Effects of glucose-dependent insulinotropic peptide on osteoclast function. Am J Physiol Endocrinol Metab (2006) 1.08
High rate of multifocality and occult lymph node metastases in papillary thyroid carcinoma arising in thyroglossal duct cysts. Ann Surg Oncol (2009) 1.08
Comment and reply on: pegfilgrastim is safe and effective in the prevention of neutropenia and treatment delays in biweekly regimens. Expert Opin Ther Targets (2013) 1.07
Imaging work-up for screening of paraganglioma and pheochromocytoma in SDHx mutation carriers: a multicenter prospective study from the PGL.EVA Investigators. J Clin Endocrinol Metab (2012) 1.06
Dominant role of CD47-thrombospondin-1 interactions in myeloma-induced fusion of human dendritic cells: implications for bone disease. Blood (2009) 1.05
Body composition variation and impact of low skeletal muscle mass in patients with advanced medullary thyroid carcinoma treated with vandetanib: results from a placebo-controlled study. J Clin Endocrinol Metab (2013) 1.05
18F-FDG PET/CT in patients with amyloid light-chain amyloidosis: case-series and literature review. Amyloid (2012) 1.05
Glucose-dependent insulinotropic polypeptide receptor knockout mice have altered bone turnover. Bone (2005) 1.03
Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial. J Clin Oncol (2012) 1.03
R115777 (Zarnestra)/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation. J Cell Physiol (2007) 1.02
Adjuvant therapy in patients with adrenocortical carcinoma: a position of an international panel. J Clin Oncol (2010) 1.02
Prognostic role of human equilibrative transporter 1 (hENT1) in patients with resected gastric cancer. J Cell Physiol (2010) 1.02
Reelin expression in human prostate cancer: a marker of tumor aggressiveness based on correlation with grade. Mod Pathol (2007) 1.02
Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing's syndrome. J Clin Endocrinol Metab (2011) 1.01
Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma. Endocr Relat Cancer (2009) 1.01
Glucose-dependent insulinotropic peptide-overexpressing transgenic mice have increased bone mass. Bone (2007) 1.01
Immunotherapy of melanoma. Semin Cancer Biol (2003) 1.01
Target therapies in pancreatic carcinoma. Curr Med Chem (2014) 1.01
GLIPR1 tumor suppressor gene expressed by adenoviral vector as neoadjuvant intraprostatic injection for localized intermediate or high-risk prostate cancer preceding radical prostatectomy. Clin Cancer Res (2011) 1.00
Multiple melanocortin receptors are expressed in bone cells. Bone (2005) 1.00
Cerebellar metastasis from pancreatic adenocarcinoma. A case report. Pancreatology (2006) 1.00
Targeted overexpression of Dkk1 in osteoblasts reduces bone mass but does not impair the anabolic response to intermittent PTH treatment in mice. J Bone Miner Metab (2010) 1.00